<DOC>
	<DOCNO>NCT00133991</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , work different way stop growth cancer cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill cancer cell . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving combination chemotherapy together rituximab may kill cancer cell . PURPOSE : This phase II trial study well give combination chemotherapy together rituximab work treat patient newly diagnose Burkitt 's lymphoma leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Rituximab Treating Patients With Newly Diagnosed Burkitt 's Lymphoma Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall response rate , 1-year event-free survival , overall survival adult patient newly diagnose Burkitt atypical Burkitt lymphoma leukemia treat dose-intensified induction therapy comprise cyclophosphamide , vincristine , prednisone , rituximab follow consolidation therapy comprise rituximab high-dose cyclophosphamide . - Determine grade 3 high non-hematologic toxic effect overall tolerability regimen patient . Secondary - Determine 3-year event-free survival overall survival patient treat regimen . - Determine general pattern CNS systemic relapse patient treat regimen . OUTLINE : This multicenter study . - Dose-intensified CVP induction therapy : Patients receive cyclophosphamide IV vincristine IV day 1 . Patients also receive oral prednisone day 1-5 rituximab IV day 1 8 , high-dose methotrexate IV leucovorin calcium IV rescue day 8 . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin day 3 continue blood count recover . Treatment repeat approximately every 14 day 2 course . - CNS therapy : Patients receive cytarabine intrathecally ( IT ) without hydrocortisone IT day 1 , 4 , 11 induction therapy course . Patients evidence CNS involvement lymphoma continue receive cytarabine IT twice weekly induction therapy treatment delay . Patients demonstrate CSF clearance receive cytarabine IT weekly 4 dos every week 4 dos consolidation therapy . Patients disease progression induction therapy persistent CNS involvement lymphoma remove study . All patient proceed consolidation therapy . - Consolidation therapy : Patients receive rituximab IV day -4 high-dose cyclophosphamide IV day -3 , -2 , -1 , 0 . Patients receive G-CSF SC daily begin day 6 continue blood count recover OR pegfilgrastim SC day 6 . Patients receive rituximab IV weekly 4 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 3 year . PROJECTED ACCRUAL : A total 30 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Classic , sporadic Burkitt 's lymphoma Burkitt 's leukemia ( FAB L3 acute lymphoblastic leukemia ) Atypical Burkitt/Burkitt'slike lymphoma leukemia , define follow criterion : Characteristic morphologic feature High proliferative index AND Ki67 â‰¥ 85 % Any stage allow Newly diagnose untreated disease Steroids allow PATIENT CHARACTERISTICS : Age 30 Performance status Not specify Life expectancy Not specify Renal No known irreversible renal dysfunction would preclude treatment highdose cyclophosphamide Cardiovascular No known significant cardiac dysfunction would preclude treatment highdose cyclophosphamide Other Not pregnant nursing No know HIV positivity No malignancy within past 3 year except basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy lymphoma A maximum 2 prior dos intrathecal chemotherapy allow Endocrine therapy Not specify Radiotherapy No prior radiation therapy lymphoma Surgery Prior complete incomplete surgical resection lymphoma allow</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>L3 adult acute lymphoblastic leukemia</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
</DOC>